MedTrace Logo

Role of Alprazolam in the Management of Acute Coronary Syndrome

NCT04715269 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-01-20

No results posted yet for this study

Summary

Cardiovascular disease has always been one of the most concerning ailments of all times considering mortality. On one end due to the emergence of pharmaceutical technology, there is a reduction in mortality, on the other hand owing to a sedentary lifestyle the incidence of this disease is increasing. Hence leading to up slopping trend in cardiovascular prevalence. Acute coronary syndrome is one of the most deadly and acute presentations of cardiology requiring immediate intervention to dampen the frequency of complications. One of the fundamental goals in the treatment of ACS is to lower the heart rate so that load on myocardial tissue can be reduced. In order to do so, we already have multiple options like beta-blockers, calcium channel blockers, and new generation ivabradine (not affecting blood pressure unlike others).

Conditions

Interventions

DRUG

Alprazolam

Alprazolam 0.5 mg will be given when the patient with acute coronary syndrome would present to the emergency

OTHER

Placebo

Empty capsule

Sponsors & Collaborators

  • Sohaib Ashraf

    lead OTHER

Principal Investigators

  • Qazi Abdul Saboor, MBBS · Shaikh Zayed Post-Graduate Medical Institute

  • Sohaib Ashraf, MBBS · Shaikh Zayed Post-Graduate Medical Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-25
Primary Completion
2021-11-15
Completion
2022-02-20

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04715269 on ClinicalTrials.gov